Table 1.

Typical clinical scenarios to consider ^99mTc‐PYP scintigraphy for suspected ATTR‐CM

Serial number	Clinical scenario
1	Family history of ATTRv amyloidosis
2	Age ≥60 years; cardiac hypertrophy on echocardiography associated with conduction disturbance, low voltage, or poor R‐wave progression on ECG
3	Age ≥60 years with HFpEF associated with unexplained LVH
4	Age ≥60 years with HFrEF associated with atrial fibrillation and LVH
5	Cardiac hypertrophy on echocardiography associated with diastolic dysfunction, right ventricular/interatrial septum/valve thickness, left ventricular sparkling, or apical sparing
6	Age ≥60 years; cardiac hypertrophy on echocardiography associated with persistently elevated hs‐cTn
7	Cardiac hypertrophy with diffuse subendocardial LGE patterns, native T1 increase, or increased ECV on CMR
8	Cardiac hypertrophy with CTS

^99mTc‐PYP, ^99mtechnetium‐pyrophosphate; ATTR‐CM, transthyretin amyloid cardiomyopathy; ATTRv, variant transthyretin; CMR, cardiac magnetic resonance; CTS, carpal tunnel syndrome; ECG, electrocardiogram; ECV, extracellular volume; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction; hs‐cTn, high‐sensitivity cardiac troponin; LGE, late gadolinium enhancement; LVH, left ventricular hypertrophy.